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RESPONSE: PROVIDING RELIEF, AVOIDING EUPHORIA 
Dennis Paul, Ph.D.; Maria A. Sullivan, M.D., Ph.D.; and Roger D. Weiss, M.D. 
Roger Weiss: I learned a lot from this article 
(Savage, Kirsh, and Passik, 2008). It pro­
vides a very comprehensive, soup-to-nuts 
review of the relationship between pain and 
substance abuse, describes the mechanisms 
of pain, and details which kinds of opioids 
cause euphoria and under what circum­
stances. Most valuably, the authors present 
a rational approach to clinically evaluating 
and treating people who have chronic pain 
and suspected or known substance abuse. 
Maria Sullivan: Many substance abuse cli­
nicians are uncomfortable with this comor­
bid population, and, conversely, pain man­
agement specialists often feel unprepared to 
handle substance issues. For those profes­
sionals in particular, the authors’ presenta­
tion of concrete clinical tools and a struc­
tured differential diagnosis of opioid misuse 
should be very helpful. 
Dennis Paul: No less important is the reminder 
that addicts deserve humane pain treatment 
just like everyone else. We have an ethical 
obligation to treat their pain. 
Universal precautions, individual 
assessments 
Sullivan: The challenge in treating pain in 
patients who have been addicted to opioids 
is to meet their therapeutic needs without 
encouraging a relapse to substance misuse. 
The authors’ recommendation for univer­
sal precautions in prescribing opioids rec­
ognizes that, even when a patient does not 
have such a history, the potential for mis­
use is always there. As the authors set them 
forth, the main precautions are, with every 
patient, to have clear treatment goals, be 
attentive to psychological and substance use 
issues, and conduct recurrent assessments 
of function as well as pain level. This strat­
egy is analogous to the use of protective 
measures, such as always wearing gloves 
when handling blood and disposing of nee­
dles safely, whether or not a patient has been 
diagnosed with an infectious disease. 
Weiss: There are obstacles to substance abuse 
patients getting pain treatment and vice 
versa. Substance abuse programs generally 
are happy to refer patients to pain programs, 
but some pain programs are reluctant to 
accept those patients. On the other hand, 
patients in pain programs typically resist the 
idea that addiction is their problem. They 
believe that chronic pain is their problem. 
Sullivan: It would be very useful for pain 
management programs to establish work­
ing relationships with addiction psychia­
trists, who can provide specialized assess­
ments of patients with potential substance 
abuse issues. As the article points out, some 
of an addiction professional’s skills, such as 
cognitive-behavioral intervention, can be 
brought to bear in pain management. 
Paul: I have encountered physicians who 
felt that addicts gave up their right to be 
treated for pain and wouldn’t give them opi­
oids. In the past, everyone who came into 
the major public hospital in New Orleans 
with a complaint of pain was suspected of 
seeking opioids. That was the mindset that 
the medical staff were instilling in students. 
We had to fight the mentality that everyone 
was looking for their next fix. 
Weiss: Giving up your right to treatment— 
I’ve never quite heard that phrase before. 
However, I think that is essentially what 
happens when people with substance abuse 
issues get thrown out of a pain clinic. It’s 
obviously a bad situation when that occurs. 
Sullivan: Most clinicians feel fairly com­
fortable treating acute pain in addicted indi­
viduals. It’s when the pain becomes chronic 
that there’s often a struggle or a difference 
of opinion over whether opioid use needs 
to continue. I’m aware of a number of patients 
who have been placed on enforced tapers 
by their pain management physician, despite 
continuing analgesic requirements and no 
current misuse of the medication. 
Weiss: Clinicians in pain treatment centers 
and primary care settings are the ones who 
most often give opioids for chronic pain. 
They are likely to suspect misuse when patients 
ask for refills sooner than scheduled or say 
they have lost prescriptions, or if an unex­
pected positive finding comes up on a urine 
screen, or if a family member reports that 
there is trouble. There are lots of reasons, 
though, why these things might occur. 
Sullivan: A common clinical response in 
those scenarios would be to curtail the sup­
ply of medication and require the patient 
to present at more frequent intervals. That 
way, care providers can get a better under­
standing of what dosing schedule the patient 
can adhere to and whether sufficient anal­
gesia is being achieved. 
Paul: At Louisiana State University, we have 
a similar procedure. We have the patients 
sign a contract, which states the exact con­
sequences of testing positive. Patients can’t 
get additional medication if they take more 
than they’re supposed to or run out too soon. 
Sullivan: At Columbia, patients who test 
positive for drugs of abuse are warned that 
they must discontinue any illicit substance 
use to remain in the program. Patients who 
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warning. The key to making such policies 
work is systematically assessing the cause of 
the abuse or misuse. Perhaps the patient’s 
pain isn’t being sufficiently alleviated. I’ve 
seen cases, such as the authors mention, 
where patients simply misunderstood dos­
ing instructions. Or a patient may be unable 
to abstain from illicit drugs if he’s not receiv­
ing adequate substance treatment. 
This is the differential diagnosis, and 
this is where pain programs can draw on the 
expertise of addiction specialists. An addic­
tion counselor can help patients distinguish 
between therapeutic and inappropriate uses 
of pain medications, and can work with 
patients to identify any psychological fac­
tors driving inappropriate use. Counselor 
and patient can discuss the role that pain 
plays in the substance problem and whether 
the patient believes that the substance abuse 
is ameliorating the pain. There are many 
possibilities to be considered before reject­
ing a patient for opioid therapy. 
Paul: The differential should also consider 
family and social dynamics, which also can 
promote pain behaviors and addictive behav­
iors. In a course that we teach on pain man­
agement, we include a section on the social 
setting of pain. We emphasize that, for some 
patients, not having to go back to work rein­
forces them for continuing to have pain. 
Others, particularly children or young adults, 
receive reinforcement for pain because their 
parents pay more attention to them, take 
care of them, and clean their room for them. 
With constant attention and reinforcement, 
the pain behavior continues. 
Sullivan: Sometimes, problems arise when 
the family has trouble relinquishing its care­
giver role after the patient recovers from 
addiction. I treated a woman who, while 
abusing opioids in her 30s, had regressed to 
very infantile behaviors. When she started 
feeling better, her parents couldn’t accept 
her autonomy and independence. In another 
case, a husband who became unemployed 
because of his overuse of prescription opi­
oids adopted a very dependent role relative 
to his wife. When he regained the ability to 
work and ceased the abuse, the couple required 
marriage counseling. 
Weiss: A very interesting, controversial ques­
tion is whether opioids themselves can con­
tribute to some patients’ pain, especially 
when they are abused. I do not know the 
answer, but I have certainly seen some of 
my addiction patients have their pain get 
better when they stopped using opioids. 
Sullivan: In my addiction psychiatry prac­
tice, I’ve also seen patients being maintained 
on opioids for pain attributed to gastroin­
testinal complaints or chronic myalgias. In 
some cases, the pattern of pain in these 
patients bore a strong resemblance to opi­
oid withdrawal syndrome and indeed remit­
ted when they were taken off the opioid. 
Potential new medical tools 
Sullivan: Currently, I’m evaluating the use 
of buprenorphine for patients with histo­
ries of prescription drug abuse who need an 
opioid-strength analgesic to control pain. I 
must say that this population is very grate­
ful to encounter clinicians who are alert to 
both their analgesic needs and their strug­
gle with addiction. They’ve often had con­
flicts with pain management specialists who 
distrust their reports of pain. They also tend 
not to feel they belong in typical substance 
abuse programs because, although they 
acknowledge a number of aberrant behav­
iors around drugs, they argue that they are 
only trying to achieve adequate pain relief. 
Our early results suggest that the patients 
in the study, who all have moderate pain, 
are achieving good relief and also having 
fewer cravings for other opioids. Also, 
buprenorphine does not seem to alter the 
analgesic effects of other opioids, so it should 
be feasible to administer additional med­
ications for episodic acute pain, for exam­
ple, in case of traumatic injury. 
Paul: I suspect that’s true of other mu opi­
oids and nonopioid analgesics. However, I 
suspect that buprenorphine alters the anal­
gesic effect of kappa-agonist opioids, such 
as butorphanol and pentazocine. 
Sullivan: We haven’t studied those specifi­
cally, but I suspect you’re right. Another 
observation we’ve made is that chronic pain 
patients are receptive to having some degree 
of control over their analgesic medication. 
During the outpatient phase of this study, 
we provide pro re nata dosing of 2 mg of 
buprenorphine, on top of the 16-mg/day 
maintenance dose. On a fixed dosing regi­
men without this measure of control for 
acute flareups of pain, patients can some­
times get into trouble and find themselves 
ahead of the count in the pill bottle. 
Weiss: We are studying buprenorphine’s abil­
ity, in conjunction with counseling, to help 
people stop abusing prescription opioids. 
Many of our study participants have pain, 
and we are monitoring, along with their sub­
stance abuse outcomes, how their pain 
responds to our treatment. I know that 
buprenorphine is used outside the United 
States for treating pain, and I’ll be interested 
to see Dr. Sullivan’s results. 
Paul: My group is experimenting with com­
binations of morphine and low-dose antipsy­
chotics, such as methotrimeprazine, which 
is currently unavailable in the United States. 
We’ve already shown that a low dose of 
methotrimeprazine can potentiate mor­
phine’s analgesic effect. 
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